Cholangiocarcinoma is the second most common primary liver cancer. Its incidence is low in
the Western world but is rising globally. Surgery, chemotherapy and radiation therapy have …

Background & Aims Cholangiocarcinoma (CCA), heterogeneous biliary tumours with dismal
prognosis, lacks accurate early diagnostic methods especially important for individuals at …

Cholangiocarcinomas (CCAs) are a heterogeneus group of malignant tumors that originate
from the biliary tract. They are usually diagnosed in advanced stages, leading to a dismal …

Patients with biliary tract cancer (BTC) show different responses to chemotherapy, and there
is no effective way to predict chemotherapeutic response. We have generated 61 BTC …

Intrahepatic cholangiocarcinoma (iCCA) is a rare, understudied primary hepatic malignancy
with dismal outcomes. Aiming to identify prognostically relevant single-nucleotide …

Abstract N6-methyladenosine (m 6 A) RNA methylation and its associated RNA-binding
protein insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) are involved in tumor …

Deubiquitylating enzymes (DUBs) play an essential role in targeted protein degradation and
represent an emerging therapeutic paradigm in cancer. However, their therapeutic potential …

Background Cholangiocarcinoma (CCA) is a very difficult-to-treat cancer. Chemotherapies
are little effective and response to immune checkpoint inhibitors is limited. Therefore, new …

Hepatitis B is a risk factor for the development of intrahepatic cholangiocarcinoma. The
prognosis of HBV-related ICC remains to be further investigated. To investigate the clinical …

The poor prognosis of most cases of advanced cholangiocarcinoma (CCA) constitutes a
severe problem in modern oncology, which is aggravated by the fact that the incidence of …